Onconova Therapeutics (NASDAQ: ONTX) Decreased to Hold at Zacks Investment Research

ONTX was devalued by Zacks.com  from a “get” score to a “hold” ranking in a research note provided to financiers on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm. It focuses on uncovering and also creating tiny particle medication candidates to deal with cancer. The Business‘s items under various phases of advancement consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Several other equities research experts also recently commented on the company. Noble Financial reissued a “get” ranking and also released a $11.00 cost goal on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 as well as established a “get” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. Business has a 50 day relocating average price of $2.90 as well as a two-hundred day moving ordinary rate of $4.16. The firm has a market cap of $46.76 million, a P/E ratio of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly revenues results on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) incomes per share for the quarter, topping experts’ consensus quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an adverse return on equity of 59.78% as well as a negative web margin of 8,294.27%. The company had earnings of $0.06 million throughout the quarter, contrasted to the agreement estimate of $0.06 million. During the same quarter in the previous year, the company uploaded ($ 0.45) EPS. En masse, research analysts anticipate that Onconova Therapeutics will publish -1.18 EPS for the present year.

A number of hedge funds have just recently bought and sold shares of ONTX. GSA Resources Allies LLP acquired a new position in Onconova Therapeutics throughout the third quarter worth $922,000. Hudson Bay Resources Monitoring LP purchased a brand-new setting in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC bought a new placement in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC bought a new position in shares of Onconova Therapeutics in the third quarter worth $493,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds and also various other institutional capitalists have 13.36% of the firm’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which participates in the recognition as well as development of oncology therapeutics. It concentrates on uncovering as well as developing little particle drug candidates to deal with cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Get a complimentary duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

For more details concerning research offerings from Zacks Investment Research, visit Zacks.com.

This instantaneous news alert was generated by narrative scientific research innovation and also monetary information from Market in order to supply readers with the fastest and most precise coverage. This story was examined by Market’s content team prior to publication. 



Prior to you take into consideration Onconova Therapeutics, you’ll wish to hear this.

Market monitors Wall Street’s premier and also best carrying out research analysts and also the stocks they advise to their customers daily. Market has determined the five stocks that top analysts are quietly whispering to their clients to buy currently prior to the more comprehensive market catches on … and Onconova Therapeutics wasn’t on the checklist.

While Onconova Therapeutics currently has a “Buy” score amongst analysts, top-rated analysts think these 5 stocks are much better gets.